Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mylan Takes “Authorized” Generics Fight To Congress, FTC, Courts

Executive Summary

Mylan is taking its fight against "authorized" generics beyond FDA to Capitol Hill, the Federal Trade Commission and the federal courts

Related Content

FTC Should Study Competitive Impact Of “Authorized” Generics, Senators Say
Teva Anticipates “Major Consolidation” In Generic Industry In 2005
Duragesic Competition Could Add To Mylan’s “Authorized” Generics Fight
GPhA Seeks Change On Medicaid “Best Price” For “Authorized” Generics
Mylan Challenge To “Authorized” Generics May Shift To Antitrust Arguments
Teva sues FDA on “authorized” generics
FDA Signs Off On “Authorized” Generics; Mylan Expected To Sue
Bristol/Teva “Authorized” Generic Agreement Approved By FTC
GPhA Wants “Authorized” Generics Stopped; Will FDA Help?
GPhA Wants “Authorized” Generics Stopped; Will FDA Help?





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts